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Abstract Much of the Spanish biotechnology industry activity operates in the Community of 
Madrid (CM). Regional and local authorities are very interested in constituting a biotechnology 
cluster in the Community. All the necessary elements can be found in the region: as shown, 
there exists the opportunity for the emergence of a biotechnology cluster in CM. However, at 
the present time no biotechnology cluster can be said to exist as such in the region; there is only 
a cluster opportunity. In order to demonstrate this proposition, we provide an overview of the 
biotechnology industry, focusing on the fi rms that operate in Madrid and their connections 
between themselves and the other actors in the system. Any cluster strategy that aims to 
develop a biotechnology cluster in Madrid should consider the form of these connections.
© 2011 Asociación Cuadernos de Economía. Published by Elsevier España, S.L. All rights reserved.
Conexiones entre empresas y oportunidad de clúster. El caso de las empresas 
biotecnológicas en la Comunidad de Madrid
Resumen Buena parte de la industria biotecnológica española opera en la Comunidad 
Autónoma de Madrid (CAM). Las autoridades regionales y locales están muy interesadas en 
constituir un cluster biotecnológico en la comunidad. Todos los elementos necesarios para que 
pueda surgir dicho cluster están presentes en la región: como se muestra en este trabajo, 
existe la oportunidad para que emerja un cluster biotecnológico en la CAM. Sin embargo, no 
se puede afi rmar con total seguridad que tal cluster exista por el momento en la región; tan 
solo hay una oportunidad de cluster. Para demostrar esta proposición, proporcionamos una 
panorámica de la industria biotecnológica centrándonos en las empresas que operan en Madrid 
y sus conexiones con otras empresas del sector y con otros actores del sistema de innovación. 
Cualquier estrategia que busque desarrollar un cluster biotecnológico en Madrid debería tener 
en cuenta la naturaleza de estas conexiones.
© 2011 Asociación Cuadernos de Economía. Publicado por Elsevier España, S.L. Todos los derechos 
reservados.
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1. Introduction
Most EU Member States are currently developing national 
and regional clusters as part of their policies to respond to 
the objectives of the Lisbon agenda. The European Cluster 
Observatory (ECO, 2010) has calculated that 38 % of the 
European labour force work in enterprises that operate as 
part of a cluster. Moreover, the ECO has identified more 
than 2,000 regional clusters in 258 of the European regions 
that were analysed.
A cluster is formed by a group of enterprises, institutions 
and R&D organisations (such as research councils, public and 
private laboratories, etc.) that share experiences and best 
practices. They also cooperate on common projects and 
coordinate their operations. Furthermore, they compete 
with each other to develop a more favourable competitive 
framework for their activities. Thus, a cluster is based on 
cooperation and innovation, and one key condition for its 
success consists of reaching a critical mass of resources within 
a geographical location. For a cluster to emerge, collaboration 
between (a) fi rms, (b) universities and R&D organizations and 
(c) regional and local authorities is of great importance.
However, the definition of cluster or the extensive 
literature on clusters does not offer a clear guide or 
objective criteria for establishing the sectoral and spatial 
limits of an industrial cluster. For example, there is nothing 
that determines a priori the detail of either the sectoral 
disaggregation that needs to be considered or the kind 
and intensity of the links between sectors and firms for 
them to be elements of a cluster. Porter himself claims 
that the delimitation of a cluster is a rather subjective 
issue that depends on the judgment of the researcher. 
This judgment usually implies a creative process that is 
determined by knowledge of the connections (or links) and 
complementarities that exist between fi rms and institutions 
(Porter, 1998, p. 202). The same degree of inaccuracy 
appears in relation to the spatial or geographical boundaries 
of a cluster, although it is obvious that the geographical 
dimension is very important to the concept of cluster: 
“A concentration of rivals, customers, and suppliers will 
promote effi ciencies and specialization. More important, 
however, is the infl uence of geographic concentration on 
improvement and innovation (Porter, 1990, p. 157).
Consequently, there is no unique guide that allows us 
to establish a priori whether the geographic boundaries 
of the clusters are more or less extensive, or in which 
spatial dimension (if any) the generating forces of a cluster 
should be operating (business linkages, externalities 
knowledge, pecuniary externalities, social networks, etc.). 
In the defi nition of cluster there is no explicit and precise 
reference to the degree of spatial density of the activities 
or the interactions between agents in a limited geographical 
space. It is impossible to set a priori a threshold from which 
objective conclusions can be drawn about the presence of 
a cluster. Therefore, the degrees of freedom of any cluster 
analysis have to be necessarily high.
These circumstances allow the researcher to establish 
a particular methodology that allows him to focus on the 
characteristics of the cluster that merit more attention in 
his opinion. In our case, we are specially interested in the 
connections of the different elements of a cluster with the 
firms that operate within it. We prefer to focus on firms 
because they are, in our opinion, the main actors in a 
cluster. Firms provide employment, incomes and profits, 
products and services and they materialise the competitive 
advantages of the cluster.
The main objective of this paper is to determine whether 
or not a biotechnology cluster exists in the Community of 
Madrid at the present time and, if not, to find the main 
reasons behind its non-emergence. To do so, we set up 
a methodology which focuses on the description of the 
existing connections between the elements that constitute 
a socio-economic system with a specific purpose (in this 
case a cluster in the Biotech industry). This methodology 
is complementary to the more traditional one based on 
Porter’s work (in the context of the Institute for Strategy and 
Competitiveness), which is based on measurements of the 
concentration and intensity of intersectoral relationships.
The paper is organised as follows: in section 2 we provide 
an overview of the main characteristics of the Spanish 
Biotechnology System of Innovation, of which the Community 
of Madrid biotechnology industry is a part. The main result 
is that, on a relative scale, the Spanish system generates 
many scientific publications but not enough patents, 
incomes and fi rms. This is said to be a common paradoxical 
characteristic of the Spanish innovation system. In section 
3 we characterise the biotechnology industry in the CM and 
analyse the existence of a biotechnology cluster. In order 
to do this, we focus on fi rms and their connections (with 
each other and with other actors in the region). We have 
employed different statistics, data sources and interviews. 
Section 4 is devoted to conclusions.
2. The Spanish Biotechnology System 
of Innovation: ‘Many publications and few 
patents’
In this section we present an overview of the main 
characteristics of Biotech industry in Spain in the period 
2000-2008. This is the common framework in which the 
different regional biotechnology concentrations of firms 
carry out their activities in Spain. Along with relative strength 
in scientifi c production, there is a marked technological and 
productive weakness. This gives rise to an apparent paradox: 
how can Spanish science be unable to generate a productive 
activity of a comparable level? Although we will not address 
this issue explicitly in this paper, some of the causes are 
repeated like a fractal dimension in the biotechnology 
industry of the Community of Madrid.
2.1. Business and fi nancial relevance of the Spanish 
biotechnology industry
Biotechnology is an emerging sector in the Spanish 
economy. The number of companies completely dedicated 
to biotechnology (CDB), i.e. firms that carry out R&D 
1. CMIB are fi rms with a consolidated activity in biotechnology either 
as their main industrial activity or as an activity that is well incorporated 
into company strategy. The fi rms with such an involvement may use the 
techniques of both modern and classical biotechnology in the 
preparation of products or processes. These firms are evolving into 
biotechnology through a process of industrial diversification. This 
terminology has been taken from Díaz et al. (2002).
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activities or invest in Biotechnology, and companies 
mainly involved in biotechnology (CMIB) 1, i.e. those that 
perform activities linked to Biotechnology to a greater or 
lesser extent(industrial and commercial enterprises) with 
interests, developments, products and services based on 
biotechnology, have shot up 70 % from 393 to 669 fi rms in 
the period 2000-2008 (Genoma España, 2009, p. 44).
By autonomous communities, there are more or less two 
CDB for each CMIB, except for Catalonia, which has a ratio 
of 3:1, and Andalusia, with 1:2 (unlike the other autonomous 
communities). In fact, Andalusia would appear to have a 
cluster of CDB (Genoma España, 2009). In any case, the 
autonomous regions with the highest number of firms are 
Madrid, Catalonia, Andalusia, Valencia and the Basque 
Country.
The most productive companies in the biotechnology 
industry (60 % of total revenues) are devoted to bio-pharmacy 
and bio-industrial processes, although they only represent 
40 % of the companies and hire 45 % of the total number of 
employees. These companies also generate 30 % of the 
employment in development and technological services, 
although they represent only 15 % of CDB with 15 % of total 
revenues.
The number of companies dedicated to diagnostics 
and vaccines, agro-biotechnology and the food sector 
are numerous and have a high level of competence. They 
contributed with 11.5 %, 8.4 % and 2.4 % of total revenues, 
respectively, in 2007 and employed 13.4 %, 9 % and 4 % 
of the total employment ure, respectively. By sectors of 
application, CBD specialize in the subsector of developments 
and technological services (29 %) while CMIB work in 
biopharmacy and account for 18 % of said subsector. The 
industry as a whole represented 0.06 % of the GDP in 2008 
(this contribution is double the fi gure for the year 2000).
Revenues grew by 32.5 % in the period 2000-2007 and the 
number of employees increased by 47.8 %. Companies have 
an average of 15 employees each and their average revenue 
is €2.57 M per company.
So far, the public administrations have been decisive in 
the development of the sector and they have been a catalyst 
for private investment. Total public expenditure on R&D 
in biotechnology in Spain (including subsidies, grants and 
refundable credits) grew 22 % per annum between 2000 and 
2008 with a maximum public investment of €1,376 M in 2007. 
The available fi gures show that 65 % of total investment in 
R&D comes from public funds and 75 % of the research staff 
(including scientists and clinical personnel) also depend on 
public funds (13,800 people); the remaining 25 % works in the 
private sector. In 2008, investments and total expenditure 
on biotechnology exceeded €1,300 M. The main fi nancier of 
the sector is the Ministry of Science and Innovation with a 
maximum of €422 M in 2007; this amount fell to €362 M in 
2008. The Ministry of Science and Innovation provides 70 % of 
total public funds, followed by the autonomous communities 
(22 %) and fi nally the EU (6 %). By sectors, public subsidies 
to R&D go to human health (71.6 %) followed by agriculture, 
livestock and fi shing (12 %). Public subsidies for innovation 
focus on food and beverages (40 %) and human health (with 
30.1 per cent).
In relation to external capital, Spain does not have 
a longstanding tradition of venture capital funding. 
Nowadays, there are 200 capital risk institutions operating 
in Spain and only 43 are pure venture capital fi rms (funding 
seed capital). Of these fi rms, 39 have been up and running 
since the year 2000 and 23 have less than fi ve years of life. 
Many fi rms are still maturing their investments and have not 
completed any disinvestment processes. Most of them are 
yet to pass the test of raising a second-round fund.
€122 M of venture capital was invested in biotechnology 
between 2005 and 2008 (fi ve times the sum for the period 
2000-2004, but far removed from the order of magnitude 
of the EU-15 (€3,600 M in the same period) and the USA 
(10,000). Compared with other sectors of the Spanish 
economy, the venture capital funding in biotechnology 
in 2006 was an average of 2.8 % higher than the EU-15; 
however this percentage fell in 2007-2008.
Most transactions are for small amounts (€0.5-3.5 M) and 
generally secured by a mix of public and private funds. TCD 
Pharma, a spin-off of the CNB, and Genmédica, a spin-off 
of the Barcelona Science Park, are two examples. It seems 
that there is lack of solid investment projects due to weak 
technological development. This circumstance must also 
be joined by the fact that Spanish biotechnological fi rms 
are not part of EURONEXT, the second market for capital in 
biotechnology.
2.2. The Scientifi c and Technological relevance 
of Spanish Biotechnology
Spain produces 3.2 % of all scientifi c papers in biotechnology 
in the world and 8.5 % of those in the EU. Spain occupied 
5th place in the EU-15 ranking of scientifi c production in 
biotechnology in 2008, preceded by Germany, UK, France 
and Italy. However, in 2000-2008, Spain increased its 
scientifi c production by 47 %, with an annual average growth 
rate of 6 % (compared with an increase of 8 % and an annual 
growth rate of 1 % in the world and the EU-15). This is 
6 times the EU-15 and world average. The percentage of the 
production of bio-science in Spain in relation to the total 
national academic production (weight) is on a level with 
Germany, France and United Kingdom.
Spain ranks 6th in the EU-15 in publications of papers in 
highest-impact factor journals. Spain’s scientific papers 
that are not related to bio-sciences account for 5.1 % of 
the EU-15 total, whereas Spanish scientists publish 8.5 % 
of the EU-15’s total papers in bio-sciences. However, only 
16.61 % of all scientifi c production in bio-science in Spain has 
a high-impact factor. Although countries such as Denmark, 
Sweden, Italy and Ireland, etc. have fewer articles than 
Spain, they achieve better impact factors for publications in 
bio-sciences. This phenomenon could be explained by a low 
level of interdisciplinary collaboration, diffi cult access to 
technologies and atomized research groups, etc.
In Spain, 25 % of total scientific research in bio is 
horizontal, following human health (19 %), industrial 
products (16 %), and agrofood (14 %). There is more 
cooperation with foreign research groups (41 %) than with 
national groups (26 %) and the rest (33 % of research groups) 
do research without collaboration. The average size of 
research teams is of 4 members.
The number  of  employees  engaged in  R&D in 
biotechnology in Spain totals 18,000 (13,900 at universities, 
hospitals and public centres and only 4,100 at biotechnology 
companies). Since 2005, this number has increased 50 % 
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in the public and private sectors. Researchers in public 
institutions account for 75 % of the total. The number of 
contracts between universities and biotechnology firms 
grew 100 % in the period 2000-2008 with the value of the 
contracts increasing more than 2.5 times. The average 
value of these contracts is approximately €30,000. There 
are also an increasing number of spin-offs from Spanish 
universities: between 13 and 15 new businesses created 
between 2006 and 2008.
Spanish institutions (universities, research councils, 
firms, etc.) doubled the number of patents requested at 
the OEPM in 2008 (200 applications in 2008 vs. 81 in 2000). 
The ratio of biotechnological patents to public researcher 
is 0.02, twice the fi gure for 2005 but a good distance from 
the fi gure for the EU-15. Spain ranks at position 11 in the 
EU-15 in European biotechnology patents granted, although 
it has improved its position somewhat, tripling from 
0.18 %in 2000 to 0.52 % in 2007 (at EPO). Germany accounts 
for 14.32 %, UK 6.05 %, France 5.95 % and the Netherlands 
2.75 % of total patents at EPO in 2008. The fi gures for patent 
applications at UPSTO are quite similar.
2.3. Spanish biotechnology: ‘a lot of publications 
and few patents’
The figures show that there are many high-quality 
publications in Biosciences in Spain; despite this scientifi c 
production, the system seems to be incapable of generating 
enough economic value through the patent system. 
United Kingdom and Germany are the three top scientifi c 
producers in biosciences in the EU-15, and they are the 
fi rst three countries in patents at EPO. Italy is the fourth 
country in bioscience in terms of scientific production 
in the EU; it accounts for 1.29 % of the total number of 
European patents. Spain, which ranks 5th in scientific 
production in Europe, accounts for only 0.52 in terms of 
total EPO. The case with inventors is the same: 46.5 per 
cent of the Spanish inventors in Biosciences are working 
abroad and transfer the ownership of their inventions to 
foreign companies. Only 47 % of Spanish inventors who are 
patent-holders live in Spain. The rest, more than half of 
the Spanish labour force with the capacity for patenting 
biotechnological innovations, live abroad and work for 
foreign institutions.
A more detailed look at the scientific production in 
Biosciences also shows that Spain is competitive in number, 
but not so much in quality (as measured by the percentage 
of papers in high impact journals). Only 16.61 % of Spanish 
scientifi c papers in Bioscience have a high-impact factor vs. 
27.85 % in UK (which occupies fi rst place in the ranking), 
the Netherlands (26.16), France (22.35), Belgium (22.28), 
Denmark, 19.78 and Italy (18.42).
For example, Holland ranks 6th in total production in the 
EU-15 (one position behind Spain); however, 26.18 % of Dutch 
publications have a maximum impact factor. Accordingly, 
Holland ranks second in the EU-15 in terms of the quality of 
its publications and fourth according to the percentage of 
EPO patents granted (preceded by UK and Germany).
If we compare the production of scientifi c papers with 
a maximum impact factor with the total of each country 
of the EU-15, 8 out of 10 countries that produce fewer 
scientific papers in absolute terms than Spain have a 
greater percentage of high impact factor papers than 
Spain. In our opinion, this fact counters the apparent 
Spanish paradox: there is a (relatively) high scientific 
production, but it is not competitive enough. This 
(relative) weakness in research quality is important for 
understanding the low-level performance of the Spanish 
biotechnology industry.
To this state of affairs, we have to add that the public 
administration plays a key role in the development of 
biotechnology in Spain, since, in practice, it depends 
on public subsidies and credit, and that the financial 
and business relevance of biotechnology in Spain is very 
low-key at the present time. Thus, despite the growth 
of sectors such as biopharmacy and industry (mainly 
biofuels) and the increasing presence of biotechnology in 
the Autonomous Communities actually, there is relative 
strength in scientifi c production and an acute weakness in 
technology and production. In Spain, there is a new 10-year 
life industry that is small and not very relevant in terms of 
revenue and employment. It is seen by society as correct, 
politically protected, funded by public budgets and it has 
a scientifi c impulse that has not been developed enough 
to produce high quality research (but it is significant in 
terms of quantity). It also encounters serious diffi culties for 
transforming the scientifi c production into market products 
and services.
The next two figures show the relative position of the 
biotechnology industry in Spain compared with USA and 
Germany. In Figure 1, we show the basic structure of the 
inputs of biotechnology fi rms, focusing on fi ve items: Public 
R&D, R&D Expenditure, Employees in Biotechnology fi rms, 
PhD in Life Sciences and Venture Capital. In order make 
these fi gures comparable across countries, we construct 
an index in which 100 represents the maximum value of 
each of the items in the corresponding leading country. 
The relative position of each country then depends on the 
distance to 100 (the best country position benchmark). The 
fi gures refer to 2008 and are taken from Genoma España 
(2009).
Figure 1 shows the relative position of Spain: it highlights 
the huge difference in fi nancial resources for biotechnology, 
Public R&D
100
50
0
Venture Capital R&D Expenditure
Employees in
Firms
PhD. on Life
Sciences
Germany Spain USA
Figure 1 An international comparison of Spanish Biotechnology: 
inputs. Data: Genoma España (2009). Own preparation.
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especially in R&D expenditure and Venture Capital, with 
6.3 and 11.9, respectively, to 100 in both values for USA. 
Paradoxically, Spain generates almost the same number of 
doctors in Life Science (77.1) as the USA (77.6).
Figure 2 shows the situation of biotechnology in Spain in 
terms of output. Using the same methodology for Figure 2, 
we highlight six items: Scientifi c Production, PCT Patents, 
EPO Patents, Patents UPSTO, Revenues and Number of 
Firms.
Figure 2 shows a signifi cant imbalance in the case of Spain 
that is also consistent with the above. Spain leads overall 
scientifi c production ahead of USA and Germany (Spain 87.5, 
USA 67.5, and Germany 63.5; although it is not shown on the 
graph, theEU-15 has a score of 100). There is no other data 
consistent with the (relative) dominant Spanish position in 
scientifi c production; the inability to generate market value 
in the form of patent output is particularly interesting. 
This is undoubtedly one of the most important issues when 
addressing a critical analysis of the position of the Spanish 
biotechnology industry.
Next, we shall see if the approach to the biotechnology 
industry in the Autonomous Community of Madrid, as a 
case study, provides us with an explanation of the above 
phenomenon.
3. The case of Biotechnology 
in the Community of Madrid
Certain cumulative circumstances in the Community of 
Madrid make it a privileged place to develop biotechnology. 
The high number of research centres, research personnel, 
universities, chemical and pharmaceutical companies, a 
large hospital network and a financial centre makes the 
Madrid bio-region an exceptional location for activities in 
this industry.
The following two tables (Table 1 and Table 2) summarize 
the number of universities that offer bio-related training 
in the Community of Madrid, together with the number of 
doctoral theses read in this and other related areas.
With regard to scientifi c position related to bioscience, 
31 % of biomedical and health sciences publications are 
done in CM. Moreover 5,000 researchers in public research 
centres and Universities are located in Madrid. As shown, 
there were 223 new doctors at universities in Madrid in 
areas related to bioscience, pharmaceuticals and veterinary 
science in 2008. 2
The main research centres in biotechnology in Spain also 
maintain their central offi ces in Madrid, such as the CNB 
(National Centre of Biotechnology), the CBM Severo Ochoa 
(a biological research centre of major importance in Spain), 
PCM (Madrid Science Park) in the UAM-CSIC international 
campus of excellence, the CSIC (the National Research 
Table 1 Number of centres where studies are offered 
by study, type and ownership
 Public 
Universities
Private 
Universities
Total
Biochemistry 3 — 4
Biotechnology 1 1 2
Biological Sciences 4 — 4
Chemical Sciences 3 1 4
Medicine 3 1 4
Pharmacy 2 2 4
Veterinary 1 1 2
Data: INE, 2010a. University Education Statistic.
Table 2 PhD Theses in bio-sciences. Academic year 2007-2008
Biochem. Biotech. Biology Chemistry Pharmacy Medicine Veterinary
 T F T F T F T F T F T F T F
Alcalá de Henares  1  0 17 13 10  6  4  3 26 13
Autónoma de Madrid 76 43 58 38 77 44
Complutense de Madrid 13 10 79 47 33 17 29 21 52 28 17 7
Rey Juan Carlos  1  1  4  3  1  1 10  6
Europea de Madrid  3
San Pablo-CEU  6  4
Data: INE. University Education Statistic. (T: total. F: females).
Scientific
Produccion
Germany Spain USA
100
50
0
40,6
64
67,8
100 100
Revenues Patents PCT
Patents EPO
Patents USPTO
100
Number of Firms
Figure 2 An international comparison of Spanish Biotechnology: 
outputs. Data: Genoma España (2009).
2. Data from Madrid Network (http://www.madridnetwork.org/
Home.aspx).
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Council), the CNIO (Spanish National Cancer Research 
Centre), the foundations Genoma España, FECYT (the 
Spanish Foundation for Science and Technology) and COTEC, 
CDTI (Centre for the Development of Industrial Technology, 
responsible for credits for innovation), etc. It is also home 
to the major business associations (such as ASEBIO and 
Farmaindustria) and scientific associations (SEBIOT) in 
the sector, the Ministry of Science and Innovation, Madrid 
Network and IMADE, etc. Finally, Madrid is the country’s 
fi nancial capital. This gives it a great advantage over other 
regions in Spain.
3.1. The Bio-region of Madrid
The definition of cluster usually implies a geographical 
dimension. Proximity is a necessary condition (but it is 
not enough) in cluster analysis. Using data provided by 
ASEBIO and BioMadrid (2010), we have identifi ed a total of 
80 companies related to biotechnology in Madrid. We have 
plotted the location of these fi rms on a map (Fig. 3) of the 
Community of Madrid and we have used the post code of 
each fi rm to locate it in the region.
The main result shows that the companies are distributed 
geographically in such a way that there is less than an hour 
of transport distance between them. There are also three 
large concentrations marked as Zones A, B and C. Zone A 
is formed by Tres Cantos, a municipal district to the north 
of the city of Madrid; this zone includes 26 fi rms. Zone B 
is formed by 30 companies in the centre-north of the city 
of Madrid. Finally, Zone B includes two municipal districts: 
Alcobendas (7 firms) and San Sebastián de los Reyes 
(5 fi rms); these districts are very close to Madrid and Tres 
Cantos. However, the most important company by size, 
revenue, employment and patents is PharmaMar, which 
is located in Colmenar Viejo, a municipal district located 
away from the capital but on the border with Tres Cantos; 
we have marked it on the map as ‘Ph.’.
The large concentration of enterprises in zone A is due to 
the location of the Madrid Science Park; most companies 
in this area are spin-offs or incubator fi rms. Furthermore, 
many of the biotechnology companies in Zone A (in the city 
of Madrid) are the central offi ces of large pharmaceutical 
fi rms or research institutions. In short, these areas identifi ed 
as A, B and C on the map include 73 of the 80 biotechnology 
fi rms operating in the Community of Madrid.
In view of this map and considering that one of the 
elements needed to identify the existence of a cluster is 
the geographical concentration of companies, it can be said 
that there is a physical grouping of fi rms in the geographical 
area of the Community of Madrid. In other words, it meets 
the necessary condition for the existence of a cluster.
3.2. Analysis of the connections
Assuming that one necessary condition for a cluster to exist 
is the geographical grouping of companies, we have to 
examine whether there are indeed important connections 
between companies and between companies and other 
actors in the industry in this area to conclude that such a 
cluster exists. To do so, we have focused on the connections 
between companies and institutions that are close to each 
other in geographical terms.
Based on the perspective of the fi rms in the bio-region 
of Madrid, we explore the connections between different 
parts or elements of the biotechnology industry. To find 
them, we had to deal with a preliminary problem: the 
limits and extension of the population of the industry. 
There is no single list of enterprises that allows us to 
identify the whole population of this industry in Madrid. 
Thus, we have used a variety of sources: ASEBIO (Spanish 
Association of Biotechnology Enterprises), BIOMADRID (an 
association of the biotechnology fi rms located in Madrid), 
fi rms of PCM (2010) (Madrid Science Park), PITEC (2007) (a 
Technological Innovation Panel that includes a survey on 
11,686 fi rms in Spain, drawn up by the INE [2010a], National 
Statistics Institute) and fi gures from Module on the use of 
Biotechnology. Year 2007, also drawn up by the INE (2010b).
Obviously, there is no unitary statistical criterion and, 
accordingly, we have performed a mix of several aspects 
from said different sources. The use of different information 
sources has led us to construct a statistical population of 
80 biotechnology-related companies in the Community of 
Madrid, 17 of which are also included in the Madrid Science 
Park (they are classifi ed as Life Sciences or Chemical fi rms).
To identify the connections in this population of 
80 companies, we have analysed the information the 
companies provide on their websites. Figure 4 shows 
information about the connections provided by the fi rms on 
their websites.
Figure 3 Map of Madrid Bio-Region (by post code). Own 
preparation.
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We have also defi ned a subset of the previous population 
that contains 17 companies located in the Madrid Science 
Park. We have gathered this information using the 
questionnaire shown in Appendix 1. 3
Comparing Figures 4 and 5, the following prominent 
features are observed. The PCM subset (Fig. 5) has more 
connections with institutes and laboratories, followed by 
connections with universities. However, the connections 
highlighted by the companies themselves (Fig. 4) on their 
websites are mostly with other companies, followed 
by institutes and laboratories, but with nearly 30 % less 
incidence of this kind of connection than in the case of 
companies located in PCM. Moreover, Figure 4 shows that 
relationships with the University are much less frequent 
than in the case of companies that are part of the PCM 
(0.40 versus 0.70).
Figure 5 also shows that there are very few connections 
between PCM fi rms and hospitals and specialized networks 
while in the case of companies in general (Fig. 4) they seem 
to mention this kind of connection more frequently.
In view of both figures, we could conclude that the 
companies belonging to the PCM (most of them spin-offs) 
focus more on connections with academic institutions or 
universities. However, companies in general have a more 
multi-relational profi le with less intensive connections that 
are more extensive with different types of agents. According 
to their own figures, the subset of PCM firms has more 
intensive relations but it seems (said with reservation) that 
they are less connected with other companies, networks 
and hospitals.
3.3. The connections of biotechnology fi rms 
in PITEC
It is very interesting to compare the previous results with 
the statistics provided by the PITEC panel data. 4 In this 
work, we have used PITEC data referred to the year 2007, 
which is the last available year at the present time.
In order to identify the main characteristics of the 
companies operating in the Community of Madrid, we have 
begun to extract the companies that have declared that 
Firms
Universities
Scientific &
Technology ParksHospitals
Specialised
networks
0,58
0,23
0,66
0,40
0,49
0,26
R&D Institutes &
Laboratories
Figure 4 Connections of biotechnology firms in CAM. Own 
preparation from the fi rms’ websites.
Firms
Universities
Scientific &
Technology ParksHospitals
Specialised
Networks
1,00
0,65
0,71
0,06
R&D Institutes and
Laboratories
0,06
0,82
Figure 5 Connections of biotechnology firms in PCM. Own 
preparation. Data from PCM.
Other firms of the
same group
1
0,5
0
Technology centres
Public research
 organisations
Universities &
Higher education
centres
Consultancy, private
laboratories and
R&D institutions
All codes Codes 0012, 0048 & 0055
Competitors
Customers
Suppliers of
equipment, material
and software
Figure 6 Connections of biotechnology firms in CAM using 
PITEC data. Own preparation using data from source: PITEC 
2007. See codes in Appendix 2.
3. This questionnaire has been drawn up by the authors. The PCM 
personnel have included some of the questions in their annual 
 report.
4. The Technological Innovation Panel (PITEC) is a statistical 
instrument for studying the innovation activities of Spanish fi rms 
over time. PITEC is designed as a panel survey. The data base is 
being built by the INE (National Statistics Institute). PITEC applies 
an anonymization process to replace the fi rm-level observations of 
six quantitative variables (Turnover, Exports Investment, Number 
of employees, Innovation expenditures and Number of R&D 
employees). The PITEC sample for 2007 includes 11,686 fi rms.
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they work in biotechnology or related activities in the Panel 
(according to NACE-93 codes). The number of companies 
after using this fi lter totals 401 companies nationwide. In 
panel 60, we have later identifi ed companies in what might 
be called a bio-region of Madrid (using the geographical 
criterion defined as ‘belonging to the Community of 
Madrid’).
With regard to collaboration, if we extract the data 
belonging to firms that have declared that they work 
in biotechnology or related activities from the PITEC 
panel, the companies reveal the following pattern of 
collaboration.
The pattern of connections of the innovative companies 
in PITEC (all companies) is not very different from the 
pattern of biotechnology-related companies; in particular, 
the fi rms associated with codes 0012, 0048 and 0055. 5 This 
is the case with regard to connections with technology 
centres, other fi rms in the same business group, suppliers of 
equipment, material and software, public research centres 
and customers. However, we fi nd a notable difference in 
connections with universities and other higher education 
institutions (67 % all vs. 80 % in the case of the selected 
subset) and consultancy fi rms and private R&D laboratories 
and institutes (50 % and 60 % respectively).
This seems to suggest that while the companies most 
closely related to biotechnology maintain a pattern of 
connections quite similar to the rest of Spanish innovative 
companies, the connections with universities and research 
centres are much more intense in the case of biotechnology 
fi rms.
Figure 7 The connections of biotechnological fi rms in the Community of Madrid. Own preparation using data from PITEC 2007. 
See PITEC codes correspondence with NACE-93 in Appendix 2. Legend: #F: number of the fi rm ordered by NACE codes and revenue. 
Location of the cooperative agent: i1: the same country; i2: other European country; i3: USA; i4: rest of the world.
Focusing specifically on the subgroup of companies 
classifi ed with PITEC codes 0012, 0048 and 0055, we obtain 
Figure 7. This figure gives a more accurate view of the 
pattern of connections of this sample of fi rms.
The fi gure is built as follows: each row represents a fi rm 
(anonymized), grouped by its corresponding PITEC code and 
ordered from higher to lower revenue. The fi gure also has 
32 columns distributed in 8 groups, depending on the type 
of agent with which a company can establish some kind of 
collaboration. Within each group there are four columns, 
since the agent that cooperates is located in Spain, another 
country of the EU, USA or the rest of the world. A shaded 
box means that there is cooperation; a blank box means no 
cooperation.
There are several elements in Figure 6 that are worthy of 
comment. First of all, 13 of the 35 companies in the table 
(those grouped under 0012, i.e. pharmaceutical fi rms) have 
an average revenue of €246 M compared to the €20.3 M of 
the 17 R&D fi rms (included in 0048). This implies that the 
former have an average revenue that is 11 times higher than 
the latter. Pharmaceutical companies spend 4.74 % of their 
revenues on internal R&D versus the 33.85 % spent by R&D 
fi rms. In other words, the latter spend 8 times more on R&D 
than the former in spite of their differences in revenues. If 
we compare the percentage of internal R&D expenditure 
with total R&D expenditures, pharmaceutical companies 
(0012) spend 64.65 % of their total R&D expenditure on 
internal R&D and companies in group 0048 spend 68.92 %.
As far as the connections are concerned, column i4 
(i = 1, … 8) is practically blank, i.e. there are no connections 
with agents other than 1, 2 and 3 (in other words, besides 
the EU and USA the fi rms in this sample have no links with 
the rest of the world).
5. See the correspondence of PITEC codes with NACE-93 codes in 
Appendix 2.
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In subgroup 0012, there are four firms (see rows 1, 6, 
7 and 13) that do not collaborate with any type of agent 
represented in the columns of the table. This is also the 
case with two companies (rows 20 and 21) in subgroup 0048.
However, firm number 8 in group 0012 shows an 
important density of connections with other companies 
in the same group. Together with the following four, this 
fi rm makes up the core of the stronger connections in the 
subsector of pharmaceutical firms. The greater intensity 
and agglomeration of connections is established with 
Consultancy, Laboratories and R&D institutions, Universities, 
Public Research Organisations and Technological Centres. 
As regards the fi rms in group 0048, the core of connections 
includes companies 14 to 19; moreover, the pattern and 
intensity of connections focus on agent groups 5, 6, 7 and 8 
(see these columns). This agglomeration (marked with a 
red circle) could be the germ of a biotechnology cluster 
in the Community of Madrid beyond corporate spin-offs or 
incubator fi rms located in PCM. In any case, this group has 
the highest density of links with groups 5-7, not with other 
fi rms, suppliers, customers and competitors, i.e. the market 
side of the cluster.
However, the companies with more intense and frequent 
connections are somewhat different. In this subclass, the 
pharmaceutical fi rms are companies with revenues ranging 
from €106 M to €3 M. The revenues of R&D fi rms range from 
€121 M to €4.4 M. Finally, group 0055 is irrelevant for the 
purposes of this analysis. 6
3.4. Regional Specialisation Index
The PITEC panel also allows us to analyze the degree of 
specialization of the Community of Madrid in biotechnology 
and compare it with other Spanish regions and the evolution 
of employment in this industry in full-time equivalent units 
(FTE). Starting with the degree of specialization, the fi gures 
for 2007 are presented in Table 3.
As in the former case, we begin with a sample of 401 
companies that have declared that they work in biotechnology 
(or related activities) in Spain; we have extracted those 
with personnel involved in R&D activities in the autonomous 
communities with more weight in this industry: Andalusia, 
Catalonia, Madrid and the Basque Country. The Index 
of Specialisation measures the proportion of employees 
involved in biotechnology R&D activities (in FTE units) in an 
Autonomous Community to total employees involved in R&D 
activities (in FTE units) in said Autonomous Community.
The table shows that 8.57 of every FTE 100 employees 
in innovative companies work in biotechnology related 
companies in the Community of Madrid. This figure has 
increased since 2005 (7.04) and 2006 (7.82), where the total 
employment in biotechnology in 2006 was 1,325.35 FTE in 
Madrid with a total of 16,958 innovative companies in the 
region.
The Spanish region with the highest degree of specialization 
in biotechnology is Catalonia due to the strong presence 
of pharmaceutical industries in the region, as well as the 
existence of frontline hospitals and universities; its research 
tradition is also more important than that of Madrid. The 
index of Andalusia should be interpreted carefully in the 
light of the relatively low total number of researchers in 
biotechnology and other activities. The value of the index in 
the Basque Country is remarkable because it is a region with 
a longstanding tradition, especially in industrial innovation, 
and it is a pioneer in the creation of technological clusters 
in Spain.
3.5. Is there a biotechnology cluster in the 
Community of Madrid at the present time?
Assuming that one necessary condition for a cluster to exist 
is the geographical grouping of companies, we focused 
on the connections between companies and between 
companies and other actors in the industry in the area in 
order to decide if a cluster actually exists. Thus, we have 
analysed the connections between companies that are 
geographically close to each other and institutions in the 
Community of Madrid.
From the above analysis, we can conclude that there is no 
biotechnology cluster, as such, in the Community of Madrid 
at the present time. We have showed that the (relative) 
predominant CM position in scientific production goes 
hand-in-hand with the inability to generate market value 
in the form of patent output, products and services (using 
revenues as a proxy) and the economic relevance of the 
biotechnology industry in the region.
Our approach to the industry of biotechnology in the 
Community of Madrid provides us with an explanation of the 
phenomenon described above: the group of fi rms that has 
the highest density of connections (with agents classifi ed in 
groups 5-7 in Fig. 7), reveal very weak connections (if any) 
Table 3 Regional Specialization Index in Biotechnology (2007)
 Biotech PR&D Total PR&D Index of Specialis. % PR&D biotech Reg/Spain % PR&D Reg/Spain
Andalusia 509.77 3,496.28 14.58 7.60 5.62
Catalonia 2,356.06 15,775.28 14.94 35.13 25.37
Madrid 1,350.75 15,754.33 8.57 20.14 25.34
Basque Country 888.55 9,494.52 9.36 13.25 15.27
SPAIN 6,706.67 62,182.16 10.79 100.00 100.00
Own preparation using PITEC 2007 data. PR&D: personnel in R&D. Units: FTE.
6. The degree of concentration of revenues in biotechnology 
companies located in Madrid (by PITEC) is very large. 20 % of the 
companies account for 87 % of the total revenues. The same applies 
to the concentration of personnel involved in R&D: 20 % of 
companies accounted for 80 % of researchers.
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with other fi rms, suppliers, customers and competitors in 
the same industry; in other words, the main weakness arises 
on the market side of a cluster.
4. Concluding remarks
The main conclusion drawn from this paper is that there 
is no biotechnology cluster as such in the Community of 
Madrid at the present time. The weakness of the existing 
connections between firms in the industry and between 
the business sector and the other biotechnology players 
supports this conclusion.
However, the region has all the elements required to 
confi gure a cluster: public and private high-level scientifi c 
research institutions, a powerful and sophisticated fi nancial 
organization, an important number of universities and 
doctors in Life-sciences, etc.
Moreover, the regional authorities have the political 
desire to set up this cluster. This is the case of the recent 
regional Madrid-Network initiative, whose projects include 
the so-called Biocluster Madrid, which aims to build a 
cluster that exploits the potential of actors present in the 
CM. There is also a cluster strategy (at least the new player 
has one). The originality of Biocluster Madrid’s approach 
consists of founding the cluster strategy on a business 
strategy (at the level of the actors involved, mainly the 
firms) instead of focusing on a more scientific-academic 
approach (as has usually been the case in Spanish cluster 
experiences).
Therefore, although we cannot speak of a biotechnology 
cluster in the CM, there is a real opportunity to create 
one. The main challenge is the generation of spaces and 
strategies for cooperation between the different actors 
involved in the industry and operating in the region of 
Madrid. These strategies must enhance the connections that 
are more concerned with markets (groups 1-4 in Fig. 7). 
The low density of this type of connection is probably 
a consequence of the fact that most pharmaceutical 
companies in Madrid are subsidiaries of multinationals and 
that R&D companies were incorporated or continue to exist 
thanks to subsidies from universities and public institutions.
Finally and from a purely theoretical point of view, 
this work shows that the density and character of the 
connections between the constituent elements of 
the system are essential to understand the dynamics and 
effi ciency of a system of innovation in particular (Encinar 
and Muñoz, 2008) and of a cluster more specifi cally.
Of course, this work is mainly descriptive: it is very 
important to have a first picture of the biotechnology 
industry in CM before designing and/or applying any cluster 
policy or cluster strategy in the region. The analysis is not 
dynamic because we do not have a long enough time series 
for more general and dynamic research (at the empirical 
and theoretical levels). Such a dynamic analysis is needed 
for a better understanding of the elements that enable the 
emergence, consolidation, and performance of a cluster.
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Appendix 1. Questionnaire used for the analysis 
of connections of Madrid Biotechnology fi rms. 
Own preparation
Firm   
URL   
Collaborations 
with:
• Universities: ………………
• R&D Institutes: ………………
• Laboratories: ………………
• Science Parks: ………………
• Technology parks: ………………
• Cluster organisations: ………………
• NGOs: ………………
• Chambers of commerce: ………………
• Specialised networks: ………………
• Public agencies:
— state ………………
— regional ………………
— local ………………
• Other fi rms: ………………
 •  Other (mass media, venture 
capital, etc.): ………………
Profi le: 1.  Was it incorporated 
as a spin-off?
❒  Y (please specify the current phase):
❒  N
2.  Was it incorporated 
as a subsidiary 
of a multinational?
❒ Y ❒ N
3. Other: ………………
4.  The location of the fi rm 
is linked to:
— Natural resources ❒ Y ❒ N
— University ❒ Y ❒ N
— Science Park ❒ Y ❒ N
— Technology park ❒ Y ❒ N
— Entrepreneur residence ❒ Y ❒ N
— Other: ………………
5. Access to Venture Capital: ❒ Y ❒ N
— Financial ❒ Y ❒ N
— Skills ❒ Y ❒ N
— Consultancy and advice ❒ Y ❒ N
6.  Connections with 
international markets 
(materials, components, 
new technologies, brain 
circulation, etc.) ❒ Y ❒ N
 Please specify:  
Pipeline/
Patents
………………
………………
Appendix 2. Correspondences of PITEC codes with NACE-93 codes
PITEC code  NACE 93 code
0012 Pharmaceutical products 244
0048 Research and Development 73
0055 Other health, social and collective services 80 (excl. 803), 85, 90, 91, 92 (excl. 921, 922), 93
